Safety and efficacy of gliclazide as treatment for type 2 diabetes: A systematic review and meta-analysis of randomized trials

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Landman, Gijs W D ^a   De Bock, Geertruide H ^b   Van Hateren, Kornelis J J ^a   Van Dijk, Peter R ^a   Groenier, Klaas H ^b   Gans, Rijk O B ^b   Houweling, Sebastiaan T ^a   Bilo, Henk J G ^a,b,c   Kleefstra, Nanne ^a  

^a Diabetes Centre   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; WEIGHT GAIN; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLICLAZIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84895750054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082880     Document Type: Article

References (41)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
2. (2008). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London.
3. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, et al. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32: 1900-1908.
4. Sadikot SM, Mogensen CE (2008) Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 82: 391-395.
5. Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide- related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86: 247-253.
6. Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, et al. (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol 9: 54.
7. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, et al. (2012) Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 14: 130-138.
8. Kardas P (2005) The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 7: 722-728.
9. Gribble FM, Reimann F (2003) Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 17: 11-15. (Pubitemid 36293503)
10. Auchampach JA, Maruyama M, Cavero I, Gross GJ (1992) Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 86: 311-319.
11. Cole WC, McPherson CD, Sontag D (1991) ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 69: 571-581.
12. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, et al. (1990) Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 247: 1341-1344.
13. Gram J, Jespersen J (1991) Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med 90: 62S-66S.
14. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS (1994) Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 11: 974-980. (Pubitemid 24375836)
15. (2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 60: 850-886.
16. (Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.).
17. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 351: 1250-1251. (Pubitemid 39296312)
18. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2005) Is this clinical trial fully registered? - A statement from the International Committee of Medical Journal Editors. N Engl J Med 352: 2436-2438. (Pubitemid 40958442)
19. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344: e1369.
20. Harrower AD (1985) Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin 9: 676-680.
21. Jerums G, Murray RM, Seeman E, Cooper ME, Edgley S, et al. (1987) Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Diabetes Res Clin Pract 3: 71-80. (Pubitemid 17025981)
22. Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF (1989) Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 15: 420-425. (Pubitemid 20076235)
23. Noury J, Nandeuil A (1991) Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab 17: 209-212.
24. Guvener N, Gedik O (1999) Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 36: 93-97.
25. Tessier D, Maheux P, Khalil A, Fulop T (1999) Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 48: 897-903. (Pubitemid 29310047)
26. Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, et al. (2001) Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 16: 296-306. (Pubitemid 32221487)
27. Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ (2003) Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med 20: 935-941. (Pubitemid 41701494)
28. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP (2004) Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27: 41-46. (Pubitemid 38196707)
29. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, et al. (2004) GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34: 535-542. (Pubitemid 39120222)
30. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P (2005) A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 22: 399-405. (Pubitemid 40516237)
31. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G (2005) Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 21: 167-174. (Pubitemid 40467663)
32. Perriello G, Pampanelli S, Di Pietro C, Brunetti P (2006) Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med 23: 246-252.
33. Ristic S, Collober-Maugeais C, Pecher E, Cressier F (2006) Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 23: 757-762. (Pubitemid 44366074)
34. Foley JE, Sreenan S (2009) Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Hormone and Metabolic Research 41: 905-909.
35. Filozof C, Gautier JF (2010) A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study. Diabetic Medicine 27: 318-326.
36. (2010) Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment. http://clinicaltrialsgov/ct2/show/NCT01022762?term=NCT01022762&rank = 1
37. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572. (Pubitemid 351831357)
38. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, et al. (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363: 1410-1418.
39. Swinnen SG, Mullins P, Miller M, Hoekstra JB, Holleman F (2009) Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 52: 38-41.
40. Vandenbroucke JP, Psaty BM (2008) Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300: 2417-2419.
41. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, et al. (2011) Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD008143.